journal article·2023-12Open access

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Huaiyuan Liang, Chunguang Yang, Ruijiang Zeng, Yingqiu Song, Jianxi Wang, Wei Xiong, Binyuan Yan, Xin Jin

Advanced Science· Volume 10· Issue 36

Abstract

Abstract The development of castration‐resistant prostate cancer (CRPC) is a significant factor that reduces life expectancy among patients with prostate cancer. Previously, it is reported that CDK4/6 inhibitors can overcome the resistance of CRPC to BET inhibitors by destabilizing BRD4, suggesting that the combination of CDK4/6 inhibitors and BET inhibitors is a promising approach for treating CRPC. In this study, candidates that affect the combined antitumor effect of CDK4/6 inhibitors and BET inhibitors on CRPC is aimed to examine. The data demonstrates that CBX3 is abnormally upregulated in CDK4/6 inhibitors‐resistant cells. CBX3 is almost positively correlated with the cell cycle in multiple malignancies and is downregulated by BET inhibitors. Mechanistically, it is showed that CBX3 is transcriptionally upregulated by BRD4 in CRPC cells. Moreover, it is demonstrated that CBX3 modulated the sensitivity of CRPC to CDK4/6 inhibitors by binding with RB1 to release E2F1. Furthermore, it is revealed that PLK1 phosphorylated CBX3 to enhance the interaction between RB1 and CBX3, and desensitize CRPC cells to CDK4/6 inhibitors. Given that BRD4 regulates CBX3 expression and PLK1 affects the binding between RB1 and CBX3, it is proposed that a dual BRD4/PLK1 inhibitor can increase the sensitivity of CRPC cells to CDK4/6 inhibitors partially through CBX3.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Breast Cancer Therapies · Protein Degradation and Inhibitors · Ubiquitin and proteasome pathways

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology The Second Xiangya Hospital Central South University Changsha Hunan 410011 China

Uro‐Oncology Institute of Central South University Changsha Hunan 410011 China

Department of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China

Cancer center Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Department of Urology The Third Hospital of Changsha Changsha Hunan 410011 China

Department of Urology Pelvic Floor Disorders Center The Seventh Affiliated Hospital Sun Yat‐sen University Shenzhen 518107 China

Funding

National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

References (53)

Show source-provided references
1. 10.3322/caac.2176310.3322/caac.21763 ↗
2. 10.3322/caac.2173110.3322/caac.21731 ↗
3. 10.1007/s40265-018-1029-910.1007/s40265-018-1029-9 ↗
4. 10.1093/annonc/mds32510.1093/annonc/mds325 ↗
5. 10.1111/j.1464-410X.2011.10643.x10.1111/j.1464-410X.2011.10643.x ↗
6. 10.1111/bju.1312310.1111/bju.13123 ↗
7. 10.1038/s41585-019-0237-810.1038/s41585-019-0237-8 ↗
8. 10.1038/nrc401610.1038/nrc4016 ↗
9. 10.1038/nm.437910.1038/nm.4379 ↗
10. 10.1038/nm.437810.1038/nm.4378 ↗
11. 10.1158/2159-8290.CD-17-060510.1158/2159-8290.CD-17-0605 ↗
12. 10.1016/j.molcel.2018.06.03610.1016/j.molcel.2018.06.036 ↗
13. 10.1038/s41467-020-17503-y10.1038/s41467-020-17503-y ↗
14. 10.1186/s12943-018-0915-910.1186/s12943-018-0915-9 ↗
15. 10.1158/1078-0432.CCR-17-357110.1158/1078-0432.CCR-17-3571 ↗
16. 10.1038/nature1322910.1038/nature13229 ↗
17. 10.1038/onc.2013.8310.1038/onc.2013.83 ↗
18. 10.1038/nrclinonc.2016.2610.1038/nrclinonc.2016.26 ↗
19. 10.3390/ijms2118647910.3390/ijms21186479 ↗
20. 10.1136/bmjopen-2019-03366710.1136/bmjopen-2019-033667 ↗
21. 10.1158/1078-0432.CCR-21-430210.1158/1078-0432.CCR-21-4302 ↗
22. 10.1158/1535-7163.MCT-20-084810.1158/1535-7163.MCT-20-0848 ↗
23. 10.1016/j.ymthe.2022.01.03910.1016/j.ymthe.2022.01.039 ↗
24. 10.1002/advs.20210088110.1002/advs.202100881 ↗
25. 10.1038/s41388-021-02114-810.1038/s41388-021-02114-8 ↗
26. 10.7150/ijbs.6898010.7150/ijbs.68980 ↗
27. 10.1016/j.molcel.2018.10.03410.1016/j.molcel.2018.10.034 ↗
28. 10.1186/s13046-019-1466-710.1186/s13046-019-1466-7 ↗
29. 10.7150/ijbs.6899510.7150/ijbs.68995 ↗
30. 10.1080/15384101.2022.206832910.1080/15384101.2022.2068329 ↗
31. 10.3390/ijms1906176810.3390/ijms19061768 ↗
32. 10.1007/s11060-019-03286-w10.1007/s11060-019-03286-w ↗
33. 10.1038/s41388-019-0815-510.1038/s41388-019-0815-5 ↗
34. 10.1016/bs.apcsb.2022.11.00910.1016/bs.apcsb.2022.11.009 ↗
35. 10.1172/JCI16664710.1172/JCI166647 ↗
36. 10.1074/jbc.M115.65559710.1074/jbc.M115.655597 ↗
37. 10.1074/jbc.M30980920010.1074/jbc.M309809200 ↗
38. 10.1038/sj.leu.240176110.1038/sj.leu.2401761 ↗
39. 10.1158/1078-0432.CCR-18-065310.1158/1078-0432.CCR-18-0653 ↗
40. 10.7554/eLife.0287210.7554/eLife.02872 ↗
41. 10.1073/pnas.05201009910.1073/pnas.052010099 ↗
42. 10.1021/acsmedchemlett.5b0008410.1021/acsmedchemlett.5b00084 ↗
43. 10.3389/fmed.2022.86999410.3389/fmed.2022.869994 ↗
44. 10.1038/s41388-022-02296-910.1038/s41388-022-02296-9 ↗
45. 10.18632/oncotarget.1525310.18632/oncotarget.15253 ↗
46. 10.1083/jcb.20101204910.1083/jcb.201012049 ↗
47. 10.1016/j.ebiom.2019.02.01210.1016/j.ebiom.2019.02.012 ↗
48. 10.1158/1535-7163.MCT-15-089710.1158/1535-7163.MCT-15-0897 ↗
49. 10.1038/srep1566610.1038/srep15666 ↗
50. 10.1016/j.ejmech.2017.05.04910.1016/j.ejmech.2017.05.049 ↗
51. 10.1093/neuonc/noab20710.1093/neuonc/noab207 ↗
52. 10.1002/med.2185910.1002/med.21859 ↗
53. 10.1016/j.tranon.2019.09.01310.1016/j.tranon.2019.09.013 ↗